The Senolytic Flavonoid

Evidence Review

Landmark Senolytic Study: Yousefzadeh et al. 2018

The study that placed fisetin at the center of longevity research was published in EBioMedicine by researchers from the Mayo Clinic and other institutions (PMID 30279143). The team screened ten flavonoids — including quercetin, luteolin, kaempferol, and apigenin — for senolytic potency in human adipocyte and endothelial cell cultures. Fisetin reduced senescent cell markers (p21, SA-β-galactosidase) by approximately 25–50% more than the next best candidate.

In mouse experiments, fisetin was administered to naturally aged mice (22–24 months, equivalent to roughly 70–80 years in humans) for 5 days, with tissue analysis following. Treated animals showed reductions in senescent cell markers across adipose, liver, brain, and lung tissue. In a lifespan experiment, mice started on fisetin at 85% of their expected lifespan showed a median lifespan extension of ~10% and improved health span metrics including better balance, muscle strength, and tissue integrity. The effect sizes were meaningful given that intervention began so late in life, and were consistent across both male and female mice. This study is the strongest preclinical evidence for any dietary flavonoid as a senolytic.

Neuroprotection in Alzheimer's Model: Currais et al. 2014

Currais et al. (PMID 24341874) used APPswe/PS1dE9 double-transgenic mice — a widely used Alzheimer's model — and fed them fisetin (500 ppm in chow) from 3 to 12 months of age. Untreated transgenic mice showed significant memory and spatial learning deficits in Morris water maze and fear conditioning tests by 12 months; fisetin-treated transgenic mice performed comparably to non-transgenic controls.

Mechanistically, fisetin reduced brain levels of p25, an aberrant protein that activates CDK5 and drives tau hyperphosphorylation and neurodegeneration. Neuroinflammatory markers (IL-6, IL-1β, TNF-α, NF-κB activation) were significantly reduced in treated animals. Importantly, amyloid-β plaque load was not reduced — indicating the cognitive preservation came from anti-inflammatory and tau-pathway modulation rather than amyloid clearance. This is relevant because amyloid-targeted therapies have largely failed in clinical trials, while anti-inflammatory approaches remain an active area of clinical investigation.

CNS Mechanisms Review: Maher 2015

Pamela Maher of the Salk Institute has published extensively on fisetin's brain effects. Her 2015 review (PMID 25961687) synthesizes decades of work on fisetin's mechanisms in the CNS, particularly its activation of the Ras-ERK-CREB signaling pathway involved in synaptic plasticity and long-term memory. Fisetin is one of very few dietary compounds shown to activate this pathway without off-target kinase effects. The review also covers fisetin's Nrf2 activation, which upregulates antioxidant response elements including glutathione synthesis — a key neuroprotective mechanism. This review provides the mechanistic foundation for human cognitive trials currently in progress.

Anti-Inflammatory Mechanism: Kim et al. 2015

Kim et al. (PMID 26336580) used LPS-stimulated RAW 264.7 macrophages to elucidate fisetin's anti-inflammatory mechanism. Fisetin inhibited the production of nitric oxide, PGE2, IL-6, and TNF-α in a dose-dependent manner. Western blotting and kinase assays identified Src and Syk as fisetin's primary molecular targets upstream of NF-κB and MAPK activation. By blocking these kinases, fisetin prevents IκBα phosphorylation and subsequent NF-κB nuclear translocation. This mechanism is complementary to quercetin (which acts more broadly on COX-2 and LOX enzymes) and helps explain why fisetin shows particular potency in neuroinflammation, where macrophage-like microglia are the primary inflammatory drivers.

Bioavailability: First Human Pharmacokinetic Study

The 2022 crossover RCT by Krishnakumar et al. (PMID 36304817) enrolled healthy adult volunteers to receive fisetin as either unformulated powder or a novel hybrid hydrogel formulation, with blood sampling at multiple timepoints. Unformulated fisetin was essentially undetectable in plasma at doses below 1,000 mg, and even at 1,000 mg, plasma levels were only quantifiable for approximately 2 hours post-dose. The hydrogel formulation produced measurably higher peak plasma concentrations and a longer time-in-circulation. This study has important practical implications: much of the preclinical evidence for fisetin used i.p. (intraperitoneal) injection or very high oral doses in rodents where gut-to-body surface-area scaling may not directly translate. For human supplementation, formulation choice significantly affects whether therapeutic plasma levels are achievable.

Overall Evidence Assessment

Fisetin has the strongest preclinical evidence of any dietary flavonoid for senolytic activity, with the 2018 Mayo Clinic study being methodologically rigorous and clinically relevant. Brain health evidence is solid in animal models, mechanistically grounded, and supported by in vitro work with human cells. Anti-inflammatory evidence in cell culture is robust. What is currently lacking is large-scale human RCT data — this is the critical gap. Several NIH-funded clinical trials in older adults and mild cognitive impairment are underway. The bioavailability challenge is real and underscores the importance of formulation. On balance, fisetin represents a scientifically compelling supplement with preclinical evidence that is unusually strong relative to most longevity compounds, but human clinical evidence remains preliminary.